MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX) announced significant corporate progress, including a $60 million collaboration with Gilead for the development of bispecific antibodies such as MGD024. The company reported a net loss of $24.8 million for Q3 2022, an improvement from $52.9 million in Q3 2021. Revenue increased to $41.7 million, boosted by milestone payments and product sales. MacroGenics anticipates initiating the Phase 2 TAMARACK prostate cancer study by year-end 2022 and expects cash runway to extend into mid-2024, supported by recent financial influxes.
- Revenue rose to $41.7 million in Q3 2022, up from $15.7 million in Q3 2021.
- Net loss decreased to $24.8 million in Q3 2022, an improvement over $52.9 million in Q3 2021.
- Received $60 million upfront payment from Gilead for MGD024 collaboration.
- Cash runway extended into mid-2024 due to recent financial support.
- Net loss of $24.8 million indicates ongoing financial challenges.
- Cash, cash equivalents, and marketable securities declined from $243.6 million at year-end 2021 to $123.6 million by September 30, 2022.
- Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced
- Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end
- Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data in first quarter of 2023
- Conference call scheduled for today at 4:30 p.m. ET
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2022.
“Over the past few months, we have strengthened our financial position by generating non-dilutive capital through our partnering efforts. We have achieved this through the receipt of
Updates on Proprietary Investigational Programs
Recent progress and anticipated events related to MacroGenics’ investigational product candidates in clinical development are highlighted below.
- MGC018, now also known as vobramitamab duocarmazine, is an antibody-drug conjugate (ADC) that targets B7-H3, an antigen with broad expression across multiple solid tumor types and a member of the B7 family of molecules involved in immune regulation.
- MacroGenics continues to expect to start the Phase 2 portion of the TAMARACK study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer (mCRPC) by year-end 2022. The Company believes that this should enable interim data from the Phase 2 portion of the study in 2024.
- Patient recruitment continues in a Phase 1/2 dose escalation study of vobramitamab duocarmazine in combination with lorigerlimab in patients with various advanced solid tumors.
- Lorigerlimab is a bispecific, tetravalent PD-1 × CTLA-4 DART molecule. MacroGenics enrolled a Phase 1/2 dose expansion study with lorigerlimab as monotherapy in cohorts of patients with microsatellite stable colorectal cancer, mCRPC, melanoma and checkpoint-naïve non-small cell lung cancer (NSCLC) and expects to provide a data update from this study in the first quarter of 2023.
- MGD024 is a next-generation, humanized CD123 × CD3 DART molecule designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. MacroGenics continues to enroll patients in a Phase 1 dose-escalation study of MGD024 in patients with CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes.
Other Program Updates:
- Teplizumab is an investigational, anti-CD3 mAb acquired from MacroGenics by Provention Bio, Inc. under an asset purchase agreement in 2018. Provention Bio is developing teplizumab for the prevention and treatment of type 1 diabetes (T1D). The Prescription Drug User Fee Act (PDUFA) target date for action on the BLA for teplizumab for the prevention of T1D is November 17, 2022. MacroGenics is eligible to receive royalties on net sales of teplizumab, if approved, in addition to milestone payments, including
$60 million upon approval of a BLA in the United States. - Retifanlimab is an investigational anti-PD-1 mAb that has been exclusively licensed to Incyte Corporation. MacroGenics is eligible to receive royalties on net sales of retifanlimab, if approved, in addition to milestone payments. In July 2022, MacroGenics received
$30 million in milestone payments from Incyte as part of its collaboration agreement. Retifanlimab is currently being studied as monotherapy or in combination with other agents across multiple studies.
Gilead Collaboration
On October 14, 2022, MacroGenics and Gilead Sciences, Inc. entered into an exclusive option and collaboration agreement to develop MGD024 and up to two additional bispecific research programs. The agreement grants Gilead the option to license MGD024. As part of the agreement, Gilead paid MacroGenics an upfront payment of
MacroGenics will be responsible for the ongoing Phase 1 study of MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study includes a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.
Third Quarter 2022 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022, were
$123.6 million , compared to$243.6 million as of December 31, 2021. The September 30, 2022 balance did not include$60 million subsequently received from Gilead in October 2022. - Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was
$41.7 million for the quarter ended September 30, 2022, compared to total revenue of$15.7 million for the quarter ended September 30, 2021. Revenue for the quarter ended September 30, 2022 included MARGENZA net sales of$4.4 million , compared to$3.6 million for the quarter ended September 30, 2021. - R&D Expenses: Research and development expenses were
$48.2 million for the quarter ended September 30, 2022, compared to$49.8 million for the quarter ended September 30, 2021. The decrease was primarily related to decreased retifanlimab manufacturing costs for Incyte, and decreased costs related to discontinued studies. These decreases were partially offset by increased development, manufacturing and clinical trial costs related to vobramitamab duocarmazine, increased expenses related to discovery projects and preclinical molecules, and increased clinical expenses related to lorigerlimab and MGD024. - SG&A Expenses: Selling, general and administrative expenses were
$15.4 million for the quarter ended September 30, 2022, compared to$17.2 million for the quarter ended September 30, 2021. The decrease was primarily related to decreased selling costs for MARGENZA as well as decreased consulting expenses. - Net Loss: Net loss was
$24.8 million for the quarter ended September 30, 2022, compared to net loss of$52.9 million for the quarter ended September 30, 2021. - Shares Outstanding: Shares of common stock outstanding as of September 30, 2022 were 61,462,189.
- Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of
$123.6 million as of September 30, 2022,$60 million subsequently received from Gilead, projected and anticipated future payments from partners and product revenues should extend its cash runway into mid-2024. This cash runway guidance reflects anticipated expenditures related to the planned Phase 2 portion of the TAMARACK study as well as MacroGenics’ other ongoing studies.
Conference Call Information
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on MacroGenics’ website for 30 days following the call.
MACROGENICS, INC.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(Amounts in thousands)
| September 30, 2022 | December 31, 2021 | ||||
| Cash, cash equivalents and marketable securities | $ | 123,616 | $ | 243,616 | |
| Total assets | 195,347 | 335,245 | |||
| Deferred revenue | 12,169 | 20,646 | |||
| Total stockholders' equity | 122,958 | 239,618 | |||
MACROGENICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(Amounts in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues: | |||||||||||||||
| Collaborative and other agreements | $ | 35,674 | $ | 11,986 | $ | 59,630 | $ | 54,338 | |||||||
| Product sales, net | 4,371 | 3,591 | 12,623 | 7,681 | |||||||||||
| Contract manufacturing | 1,142 | — | 5,134 | — | |||||||||||
| Government agreements | 547 | 85 | 1,455 | 1,281 | |||||||||||
| Total revenues | 41,734 | 15,662 | 78,842 | 63,300 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of product sales | 3,007 | 1,665 | 3,235 | 1,704 | |||||||||||
| Cost of manufacturing services | 136 | — | 2,358 | — | |||||||||||
| Research and development | 48,191 | 49,823 | 161,373 | 158,724 | |||||||||||
| Selling, general and administrative | 15,355 | 17,161 | 45,277 | 47,431 | |||||||||||
| Total costs and expenses | 66,689 | 68,649 | 212,243 | 207,859 | |||||||||||
| Loss from operations | (24,955 | ) | (52,987 | ) | (133,401 | ) | (144,559 | ) | |||||||
| Other income | 142 | 101 | 841 | 466 | |||||||||||
| Net loss | (24,813 | ) | (52,886 | ) | (132,560 | ) | (144,093 | ) | |||||||
| Other comprehensive income (loss): | |||||||||||||||
| Unrealized gain (loss) on investments | 213 | (4 | ) | (52 | ) | 4 | |||||||||
| Comprehensive income (loss) | $ | (24,600 | ) | $ | (52,890 | ) | $ | (132,612 | ) | $ | (144,089 | ) | |||
| Basic and diluted net loss per common share | $ | (0.40 | ) | $ | (0.86 | ) | $ | (2.16 | ) | $ | (2.42 | ) | |||
| Basic and diluted weighted average common shares outstanding | 61,459,831 | 61,169,754 | 61,390,143 | 59,494,836 | |||||||||||
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, MARGENZA and DART are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, including initiation and enrollment in clinical trials, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA and the Company’s product candidates, if approved, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that MGC018, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to MGC018, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, the availability of financing to fund the development of our product candidates, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, expectations of future milestone payments, the impact of competitive products, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business, or economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises such as the novel coronavirus (referred to as COVID-19 pandemic), and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com
FAQ
What are the recent financial results for MacroGenics (MGNX) for Q3 2022?
What is the status of the MGC018 TAMARACK study?
How did MacroGenics strengthen its financial position in 2022?
What is the anticipated cash runway guidance for MacroGenics?
What is the significance of the collaboration with Gilead for MGD024?
